Axela生物傳感器
階段
Unattributed VC -二世 |活著總了
5.8美元關於Axela生物傳感器
Axela交付的使命是提供一個簡單而有效的方法來個性化醫療利用dotLab體係在研究市場今天創造明天的診斷。這個策略提供一個共同的技術平台,充分利用兩個市場的目標是提供一個機會發現。方法已經導致應用程序地址段的潛力大,服務水平低下的癌症和心髒病學市場的焦點將安裝兩個今年夏天資助的臨床試驗和不斷增長的客戶群。一段時間這些領先的臨床研究人員可以利用蛋白質相互作用的直接理解發展定量分析在單一平台。點技術縮短了從蛋白質發現過渡到應用程序。能夠實時測量生物分子複合物旨在提供疾病管理的新方法。
缺失:Axela生物傳感器的產品演示和案例研究
促進你的產品提供技術買家。
達到1000年代的買家使用CB的見解來確定供應商,演示產品,188bet游戏做出購買決定。
缺失:Axela生物傳感器的產品&微分器
不要讓你的產品被跳過。買家使用我們的供應商排名名單公司和驅動(rfp)請求建議。
專家集合包含Axela生物傳感器
專家集合是analyst-curated列表,突出了公司你需要知道的最重要的技術空間。
Axela生物傳感器中2專家集合,包括癌症。
癌症
4784件
製藥和生物技術公司與癌症治療藥物的候選人。
生物製藥技術
5241件
公司參與研究、開發和商業化的化學或生物衍生& theranostic治療藥物。不包括維生素/補充劑,橫/臨床試驗服務。
Axela生物傳感器專利
Axela生物傳感器已經提出12項專利。
3最受歡迎的專利主題包括:
- 分析化學
- 集群的區別
- EC 3.4.24
申請日 |
授予日期 |
標題 |
相關的話題 |
狀態 |
|---|---|---|---|---|
|
2/22/2018 |
4/19/2022 |
流體動力學、分析化學、流體力學、質譜分析、閥門 |
格蘭特 |
申請日 |
2/22/2018 |
|---|---|
授予日期 |
4/19/2022 |
標題 |
|
相關的話題 |
流體動力學、分析化學、流體力學、質譜分析、閥門 |
狀態 |
格蘭特 |
最新的Axela生物傳感器新聞
2018年8月22日
摘要Axela公司Axela,以前Axela生物傳感器公司是光學技術解決方案的提供者。公司提供Ziplex係統Flowthru TipChips, panelPlus TipChips,衍射光學技術、衍射光學傳感器,panelPlus傳感器和軟件產品。它提供了技術和應用支持,現場和自身的培訓,延長保修,服務和維護合同;和自定義應用程序開發服務。公司和內容創建工具來簡化多元生物標誌物檢測轉化研究和診斷測試。市場其產品通過網絡經銷商在加拿大、愛爾蘭、比利時、盧森堡、西班牙、荷蘭、英國和美國。Axela總部位於多倫多,安大略省,加拿大。Axela公司醫療設備交易和聯盟為您提供全麵的數據和趨勢分析公司並購的MAs,夥伴關係和融資。報告提供詳細信息的並購,股票/債券發行、私募股權、風險融資和合作公司交易記錄的一個五年計劃。報告提出了詳細的比較數據,交易數量和他們的價值分為交易類型,界別分組和地區。 GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Axela生物傳感器常見問題(FAQ)
Axela生物傳感器的總部在哪裏?
Axela生物傳感器的總部位於50榮森,多倫多。
Axela生物傳感器的最新一輪融資是什麼?
Axela生物傳感器的最新一輪融資是Unattributed VC - II。
Axela生物傳感器籌集了多少錢?
Axela生物傳感器籌集了總計5.8美元。
Axela生物傳感器的投資者是誰?
Axela生物傳感器的投資者包括MMV金融、VG夥伴,門檻企業和卡溫頓基金。
Axela生物傳感器的競爭對手是誰?
Axela生物傳感器的競爭對手包括Sesen生物、MolecularMD Amnis公司Inotek製藥、地區,Everist健康,Evogen, BioVidria Lipomics技術、卡尺生命科學和15。
競爭對手比較Axela生物傳感器
變化有幾個研究項目在基礎科學領域,將提高我們對癌症的理解過程,包括項目豐富的功能基因組學。他們有長期承諾的發展項目,促進這些基本的翻譯科學發現轉化為攻擊癌症治療策略,從而改善人類健康。
固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
智能醫療設備,dba IntelligentMDx,研發和製造測試,根據法規遵從性,基於廣泛的分子係統用於臨床分子診斷、藥物開發和應用科學的應用。它的目的是翻譯的需要臨床醫生,病人和合作夥伴到非常具體的,高度敏感,健壯的臨床有效的測試,從而使護理人員在全球範圍內改善病人護理。
Chalex集團的組成有房間的麥克馬斯特大學研究人員所使用的幻燈片是計數,實驗室,nematologists獸醫從業人員在世界各地。明確的耐用丙烯酸為長期使用,公司的幻燈片也特性精確量由於射出成型精度產生一致的測試結果比其他幻燈片與手工室間距器。這些幻燈片的質量使其世界各地的標準。
ReaMetrix, inc .)是一個美國和印度生物技術公司旨在提供高質量的研究和診斷試驗解決方案導致印度的機會成本轉變成價值的生物技術和全球衛生部門。ReaMetrix相信印度的資源會帶來重要價值識別和解決發展中國家的衛生保健需求,和由此產生的產品往往會帶來更多的負擔得起的替代產品在發達國家。
Everist健康(原名Everist基因組學和遺傳學的平方)是一個個性化醫療公司開發和獨占鼇頭醫學獨特的診斷、預測和治療選擇技術。通過他們的工具,該公司旨在幫助醫生提高醫療效果和減少護理的總成本。EGI的產品集成移動數字服務,智能手機和平板電腦導致先進的醫療技術。
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。